We choose indications by asking ourselves, “What problems are patients facing that need to be solved?”. Then, we use our scientific insights combined with our proprietary platform to highlight opportunities outside commonly-practiced approaches.
Spinal Muscular Atrophy
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Apitegromab (selective anti-latent myostatin)
Apitegromab (Myostatin-Related Disorders)
Myostatin-Related Disorders
Next Anticipated Milestone: Identify second indication for apitegromab
Target: Pro/Latent Myostatin
Description: Myostatin-Related Disorders
Immuno-Oncology
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
SRK-181 (Selective context-independent, anti-latent TGFβ-1)
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Selective anti-RGMc
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Selective context-dependent (LTBP1 & LTBP3) anti-latent TGFβ-1
Cardiometabolic
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Novel anti-myostatin antibody (selective anti- pro and latent myostatin)
Clinical Trials
We focus on the discovery and development of safe and effective therapies to find optimal solutions for those who need it.
Partnerships
Help us shed light on the subject. Collaborate with us to uncover enlightened solutions for patients.